SEC Filing Summary for Cullinan Therapeutics, Inc.

Kynam Capital Management, LP, along with Kynam Capital Management GP, LLC and Yue Tang, has reported beneficial ownership of 3,114,132 shares of Cullinan Therapeutics, Inc. common stock, representing 5.27% of the class. This ownership was acquired as of December 31, 2025. The filing, designated as a SCHEDULE 13G, indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer. Kynam Capital Management, LP is identified as an investment adviser (IA), Kynam Capital Management GP, LLC as an other organization (OO), and Yue Tang as an individual (IN). All three share shared voting and dispositive power over the reported shares.